NVSEF News and Press, Novartis Ag Basel Akt From 07/13/20

Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...

Quick Take Annexon ( ANNX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma developing antibodies for treating autoimmune and neurodegenerative diseases. ANNX is targeting a number of s...

Quick Take Poseida Therapeutics ( PSTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing immuno-oncology and genetic-based treatments for various cancer indications. PSTX is still at a very early stag...

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...

Quick Take Poseida Therapeutics ( PSTX ) has filed to raise $115 million in an IPO of its common stock, according to an S-1 registration statement . The firm is advancing a broad pipeline of genetic and CAR-T-based therapies for blood, solid, and other cancers. PSTX has achieved promisi...

Quick Take Greenwich LifeSciences ( GLSI ) has filed to raise $23.5 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing an immunotherapy designed to prevent the recurrence of breast cancer. GLSI is preparing to enter Phase 3 trials ...

Quick Take Forma Therapeutics Holdings ( FMTX ) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement. The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers. FMTX...

The following slide deck was published by Novartis AG in conjunction with this Read more ...

Quick Take Akouos ( AKUS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing genetic treatments for hearing loss. AKUS won’t enter trials for its lead candidate until 2021, with initial data reado...

This article is part of a series that provides an ongoing analysis of the changes made to Tweedy, Browne's 13F portfolio on a quarterly basis. It is based on Tweedy, Browne's regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Tweedy, Browne Portfolio series to get an idea o...